Nutriband Inc. (NTRB)

Market Cap	90.16M
Revenue (ttm)	2.40M
Net Income (ttm)	-9.97M
Shares Out	11.13M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,543
Open	8.01
Previous Close	8.04
Day's Range	8.01 - 8.11
52-Week Range	3.72 - 11.78
Beta	1.23
Analysts	Buy
Price Target	13.00 (+60.49%)
Earnings Date	Sep 2, 2025

About NTRB

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRB
• Website: https://www.nutriband.com

Financial Performance

In 2024, Nutriband's revenue was $2.14 million, an increase of 2.60% compared to the previous year's $2.09 million. Losses were -$10.48 million, 91.1% more than in 2023.

Analyst Summary

According to one analyst, the rating for NTRB stock is "Buy" and the 12-month stock price target is $13.0.

Price Target

$13.0

(60.49% upside)

Analyst Consensus: Buy